OMERS ADMINISTRATION Corp Has $6.39 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

OMERS ADMINISTRATION Corp cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 69,183 shares of the biopharmaceutical company’s stock after selling 733 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Gilead Sciences were worth $6,390,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after buying an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock valued at $3,293,822,000 after acquiring an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock worth $2,608,337,000 after purchasing an additional 749,047 shares in the last quarter. Norges Bank acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $1,789,254,000. Finally, Northern Trust Corp grew its position in shares of Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on GILD shares. Morgan Stanley increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. Piper Sandler increased their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Bank of America increased their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total transaction of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares in the company, valued at approximately $17,893,713.60. The trade was a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 22,929 shares of company stock worth $2,644,895 in the last ninety days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $101.43 on Wednesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The firm has a market capitalization of $126.30 billion, a P/E ratio of 274.14, a P/E/G ratio of 0.71 and a beta of 0.26. The company’s 50 day moving average price is $106.71 and its two-hundred day moving average price is $99.51.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter last year, the business posted ($1.32) EPS. Gilead Sciences’s revenue for the quarter was down .3% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 3.12%. Gilead Sciences’s dividend payout ratio is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.